top of page

State of Possible: On the one-year anniversary of the spin-out of Seaport Therapeutics, Daphne Zohar describes the Glyph platform that powers it, and her thoughts on running depression trials

4 days ago

She describes the idea of leveraging Glyph to achieve oral dosing of medicines in cases where it would not be possible or tolerable. Plus, the lead clinical program, allopregnanolone, how the company thinks about avoiding high placebo responses in trials, and other programs.

Recent Posts

Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry

Miami based Galatea Bio raised $25M today to expand its 'Galatea Global Biobank', an initiative to sequence 10 million participants worldwide, with a focus on individuals of non-European ancestry

State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies

State of Possible: Winner of the MassBioDrive Startup of the Year Award last year, the Co-Founder and CEO of Eascra Biotech describes developing nanoparticles as a delivery vehicle for therapies

State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech

State of Possible: Beam Therapeutics' CEO John Evans discusses the company's recent alpha-1 antitrypsin deficiency data, what's ahead for sickle cell disease, and the current environment for biotech

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Allucent Clinical Research Organization™ is on a mission to help bring new therapies to light by solving the distinct challenges of small and mid-sized biotech companies. We’re a global provider of comprehensive drug development solutions, including consulting, clinical operations, biometrics, and clinical pharmacology across a variety of therapeutic areas.

Learn more about Allucent

bottom of page